Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.675
Bid: 1.65
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.05 (3.03%)
Open: 1.675
High: 1.725
Low: 1.625
Prev. Close: 1.675
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Posting of Annual Report and Accounts

4 Nov 2009 14:38

RNS Number : 9564B
Epistem Holdings plc
04 November 2009
 

For release: 4 November 2009

Epistem Plc 

("Epistem" or the "Company")

Posting of Annual Report and Accounts

Epistem Plc (LSE: EHP)the rapidly growing UK biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases, confirms that its Annual Report and Accounts for the year ended 30 June 2009 and notice of AGM were posted to shareholders on 2 November 2009. 

An electronic copy of the Annual Report and Accounts is available on the Investor Centre section of the Company's websitewww.epistem.co.uk.

For further details, please contact:

Epistem Plc

Matthew Walls CEO +44 (0) 161 606 7258

John Rylands CFO

Piper Jaffray Ltd.

Neil Mackison, Graeme Smethurst +44 (0) 0203 142 8700

Corporate Broking: Jamie Adams

Mike Wort / Anna Dunphy +44 (0) 207 861 3838

De Facto Communications

About Epistem:

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases, dermatology and ageing. Epistem provides specialised pre-clinical efficacy testing, biomarker services and develops proprietary novel therapeutics for partnership and development with drug development companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSZGMGMDDRGLZM
Date   Source Headline
2nd Jun 202312:25 pmRNSEquity Prepayment Facility drawdown
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension
30th Mar 20237:00 amRNSPositive final recommendation by NICE
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
20th Mar 20237:00 amRNSCommence of roll out in Greater Manchester
9th Feb 20232:05 pmRNSSecond Price Monitoring Extn
9th Feb 20232:00 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSAIHL test preliminary recommendation by NICE
27th Jan 20232:05 pmRNSSecond Price Monitoring Extn
27th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
25th Jan 20234:40 pmRNSSecond Price Monitoring Extn
25th Jan 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20234:40 pmRNSSecond Price Monitoring Extn
19th Jan 20234:35 pmRNSPrice Monitoring Extension
29th Dec 20226:10 pmRNSResult of AGM
5th Dec 20227:00 amRNSNotice of AGM
30th Nov 20227:00 amRNSBlock Listing Six Monthly Return
21st Nov 20227:00 amRNSAudited Final Results
14th Nov 20227:00 amRNSNotice of Results
24th Oct 20227:00 amRNSGrant of options
5th Oct 20224:40 pmRNSSecond Price Monitoring Extn
5th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSUS FDA pre-submission for Genedrive MT-RNR1 kit
26th Sep 20227:00 amRNSNICE to accelerate evaluation of Genedrive test
22nd Aug 20227:00 amRNSNICE includes CYP2C19-ID Kit in new programme
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:00 pmRNSPrice Monitoring Extension
16th Jun 20227:00 amRNSNICE to evaluate the Genedrive® MT-RNR1 Test
30th May 20229:05 amRNSSecond Price Monitoring Extn
30th May 20229:00 amRNSPrice Monitoring Extension
30th May 20227:00 amRNSPoint-of-Care COV19-ID Kit receives CTDA approval
27th May 20227:00 amRNSBlock listing Interim Review
25th Apr 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.